Although there is a lot of hope and optimism surrounding immunotherapy, Marion Subklewe, MD, of the University of Munich, Munich, Germany, emphasizes that patients should be well informed on the pros and cons involved. For acute myeloid leukemia, patients should firstly be offered the most effective approved therapies. This interview was recorded at the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
AML immunotherapy: patients need to be well informed
